Albert David Limited has informed the Exchange that Board of Directors at its meeting held on May 13, 2025, recommended Final Dividend of 5 per equity share.
ALBERTDAVD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.9 pts less than Nifty Microcap 250 and 7.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Albert David Limited (pharmaceuticals, Kothari Group) announced audited results for Q4 and FY ended March 31, 2025, with an unmodified audit opinion from L.B. Jha & Co. Revenue from operations fell to Rs. 345.77 crore in FY25 from Rs. 362.46 crore in FY24, a decline of about 4.6%. Profit before tax dropped sharply to Rs. 25.23 crore from Rs. 97.29 crore (down ~74%), with FY25 PAT at Rs. 17.20 crore vs Rs. 75.42 crore earlier (down ~77%). Q4 FY25 actually slipped into a loss of Rs. 10.33 crore, hurt by negative 'other income' (mark-to-market losses on investments). Operating cash flow turned sharply negative at Rs. (28.44) crore vs Rs. 45.50 crore inflow last year. The Board recommended a final dividend of Rs. 5 per share (50% on face value of Rs. 10), subject to shareholder approval at the AGM on August 2, 2025 (record date July 25, 2025). PwC Services LLP was reappointed as Internal Auditor, S. Gupta & Co. as Cost Auditor, and MKB & Associates appointed as Secretarial Auditor for 5 years.
The results are weak on a full-year basis—revenue, profits, and cash flow all declined sharply despite the dividend payout, which may weigh on short-term sentiment. However, the unchanged Rs. 5 dividend signals management's confidence in cash buffers and continuity of shareholder returns.